Prevention & lipidsRandomised controlled trial

Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial

Eur Heart JPublished

  • Randomised controlled trial
  • placebo-controlled

Authors' conclusion

Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD.

Study context

Population
Adults in Germany with Lp(a) >60 mg/dl and established cardiovascular disease (CVD) who had undergone ≥35 lipoprotein apheresis sessions in the prior year25 of 26 pelacarsen, 23 of 25 placebo completed
Participants
51 adults
Comparison
Pelacarsen vs placebo
  • Pelacarsenn = 26
  • Placebon = 25reference
Primary endpoint
Rate of performed lipoprotein apheresis sessions normalised to the weekly schedule (actual/planned sessions)
Follow-up
52 weeks

Primary result

Rate of lipoprotein apheresis

Odds ratio

0.006

95% CI 0.003–0.013

P < 0.0001

By group

Pelacarsen

0.16

mean

Placebo

0.93

mean

Pelacarsen vs Placebo
OR 0.006 (95% CI 0.003–0.013); P < 0.0001

As reported in the abstract

Secondary outcomes

Outcomeplacebo-adjusted change (%) (95% CI)P value
Placebo-adjusted Lp(a) change from baseline · week 52−72 (−79% to −61%)P < 0.0001
OutcomePelacarsenPlaceboEstimateP value
Time to lipoprotein apheresis avoidance (≥24 consecutive weeks)median time 6.1 weeksNot reported in the abstractHR 88.3P = 0.0014
Total lipoprotein apheresis avoidance · week 12 to week 52OR 163.2P = 0.0005

Safety

Injection site erythema (mostly mild)

Injection site erythema (mostly mild)

Treatment-emergent adverse events similar between arms

Original publication

Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Eur Heart J. Published 21 February 2026. doi:10.1093/eurheartj/ehag073

Summarised from the published abstract; every number is checked against it